Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy
Authors
Keywords
-
Journal
FEBS Journal
Volume 286, Issue 18, Pages 3510-3539
Publisher
Wiley
Online
2019-07-23
DOI
10.1111/febs.15011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage.
- (2019) Marcus Smith Noel et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
- (2019) Gabriel Mak et al. BRITISH JOURNAL OF CANCER
- Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study
- (2019) Dean A. Fennell et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Status of Immunotherapies for Treating Pancreatic Cancer
- (2019) Annie A. Wu et al. Current Oncology Reports
- Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC)
- (2018) Jia Lin Er et al. APOPTOSIS
- MTOR inhibitor-based combination therapies for pancreatic cancer
- (2018) Zonera Hassan et al. BRITISH JOURNAL OF CANCER
- Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
- (2018) Rajani Kanteti et al. CANCER BIOLOGY & THERAPY
- Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma
- (2018) Guang-Tao Yu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells
- (2018) Fiona Simpkins et al. CLINICAL CANCER RESEARCH
- Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non–Small-cell Lung Cancer: A Phase I Study
- (2018) Carole Massabeau et al. Clinical Lung Cancer
- EGFR family and Src family kinase interactions: mechanics matters?
- (2018) Zhongwen Chen et al. CURRENT OPINION IN CELL BIOLOGY
- Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’
- (2018) M. Haas et al. EUROPEAN JOURNAL OF CANCER
- Galectin-3 Mediates Tumor Cell–Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling
- (2018) Wei Zhao et al. GASTROENTEROLOGY
- Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer
- (2018) Claire Vennin et al. GASTROENTEROLOGY
- Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy
- (2018) Mopa Alina Sooro et al. INTERNATIONAL JOURNAL OF CANCER
- HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
- (2018) Sunil R. Hingorani et al. JOURNAL OF CLINICAL ONCOLOGY
- Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
- (2018) Thierry Conroy et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
- (2018) Yiyin Zhang et al. Journal of Hematology & Oncology
- Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study
- (2018) Yuho Najima et al. LEUKEMIA RESEARCH
- Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
- (2018) Kodappully S. Siveen et al. Molecular Cancer
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Spatially modulated ephrinA1:EphA2 signaling increases local contractility and global focal adhesion dynamics to promote cell motility
- (2018) Zhongwen Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ASCO- und ESMO-Update 2017 – Neuigkeiten vom 53. Meeting der American Society of Clinical Oncology/ASCO 2017 und European Society for Medical Oncology/ESMO-Congress 2017
- (2018) Thomas Ettrich et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
- (2018) Anjali V. Sheahan et al. Oncotarget
- Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer
- (2018) James R.W. Conway et al. Cell Reports
- Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
- (2018) Divya Murthy et al. Frontiers in Physiology
- A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma
- (2018) Irene S. Yu et al. Canadian Journal of Gastroenterology and Hepatology
- Activation of Hepatic Stellate Cells During Liver Carcinogenesis Requires Fibrinogen/Integrin αvβ5 in Zebrafish
- (2018) Chuan Yan et al. NEOPLASIA
- Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcitabine (G).
- (2018) Song Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic and transcriptional evolution alters cancer cell line drug response
- (2018) Uri Ben-David et al. NATURE
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- 1326PEvaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors
- (2018) A Koumarianou et al. ANNALS OF ONCOLOGY
- Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
- (2018) James RW Conway et al. GUT
- IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma
- (2018) Giulia Biffi et al. Cancer Discovery
- Focal adhesions: a personal perspective on a half century of progress
- (2017) Keith Burridge FEBS Journal
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results
- (2017) Dana B. Cardin et al. INVESTIGATIONAL NEW DRUGS
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Pro-migratory and TGF-β-activating functions of αvβ6 integrin in pancreatic cancer are differentially regulated via an Eps8-dependent GTPase switch
- (2017) Jo Tod et al. JOURNAL OF PATHOLOGY
- Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non–Small Cell Lung Cancer
- (2017) Bo Zhou et al. JNCI-Journal of the National Cancer Institute
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer
- (2017) Angela M. Krebs et al. NATURE CELL BIOLOGY
- E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells
- (2017) T Kato et al. ONCOGENE
- SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer
- (2017) N L E Harris et al. ONCOGENE
- The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma
- (2017) Asma Begum et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis
- (2017) Claire Vennin et al. Science Translational Medicine
- Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin
- (2017) De-Bo Kong et al. OncoTargets and Therapy
- Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
- (2017) Kit Man Wong et al. Current Oncology Reports
- c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis
- (2017) Jia Zhang et al. Nature Communications
- Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update
- (2017) Laure Malric et al. Oncotarget
- A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts
- (2017) Max Nobis et al. Cell Reports
- Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence
- (2017) Janusz Franco-Barraza et al. eLife
- Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non–Small Cell Lung Cancer
- (2017) Bo Zhou et al. JNCI-Journal of the National Cancer Institute
- Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models
- (2017) Can Hekim et al. Cancer Immunology Research
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
- (2017) Ashton A. Connor et al. JAMA Oncology
- A phase I dose-escalation study of IMGN388 in patients with solid tumors.
- (2017) D. S. Thompson et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.
- (2017) Jon Kroll Bjerregaard et al. JOURNAL OF CLINICAL ONCOLOGY
- Src kinases play a novel dual role in acute pancreatitis affecting severity but no role in stimulated enzyme secretion
- (2016) Bernardo Nuche-Berenguer et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2016) J. C. Soria et al. ANNALS OF ONCOLOGY
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- The complexity of integrins in cancer and new scopes for therapeutic targeting
- (2016) Hellyeh Hamidi et al. BRITISH JOURNAL OF CANCER
- mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
- (2016) David R. Driscoll et al. CANCER RESEARCH
- TGF-β Tumor Suppression through a Lethal EMT
- (2016) Charles J. David et al. CELL
- Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
- (2016) S. R. Hingorani et al. CLINICAL CANCER RESEARCH
- Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
- (2016) Sandra P. D'Angelo et al. CLINICAL CANCER RESEARCH
- Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2016) M. Hussain et al. CLINICAL CANCER RESEARCH
- New insights in the development of pancreatic cancer
- (2016) Smrita Sinha et al. CURRENT OPINION IN GASTROENTEROLOGY
- ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth
- (2016) Nicola Rath et al. EMBO Molecular Medicine
- Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
- (2016) Sonja M. Wörmann et al. GASTROENTEROLOGY
- Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer
- (2016) Liang Mao et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Perioperative stromal depletion by PEGPH20 in pancreatic ductal adenocarcinoma.
- (2016) Andrew H. Ko et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis
- (2016) Ami Patel et al. LIFE SCIENCES
- Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling
- (2016) Emily S. Humphrey et al. MOLECULAR & CELLULAR PROTEOMICS
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
- (2016) Kiruthikah Thillai et al. Oncotarget
- Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
- (2016) Daniela Massihnia et al. Oncotarget
- Focal Adhesion Kinase Regulates Fibroblast Migration via Integrin beta-1 and Plays a Central Role in Fibrosis
- (2016) Xue-Ke Zhao et al. Scientific Reports
- Intravital FRAP Imaging using an E-cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic Regulation of Cell-Cell Junctions in Live Tissue
- (2016) Zahra Erami et al. Cell Reports
- FAK goes nuclear to control antitumor immunity—a new target in cancer immuno-therapy
- (2016) Alan Serrels et al. OncoImmunology
- The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases
- (2015) James Ozanne et al. BIOCHEMICAL JOURNAL
- Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread
- (2015) Ping-Pui Wong et al. CANCER CELL
- Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/ -Catenin Signaling
- (2015) M. Quan et al. CANCER RESEARCH
- Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
- (2015) P. Pettazzoni et al. CANCER RESEARCH
- Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis
- (2015) Amine Sadok et al. CANCER RESEARCH
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities
- (2015) Venessa T. Chin et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer
- (2015) S. M. Reddy et al. INVESTIGATIONAL NEW DRUGS
- A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2015) Suzanne F. Jones et al. INVESTIGATIONAL NEW DRUGS
- Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma
- (2015) Viktoria Laszlo et al. JOURNAL OF PATHOLOGY
- Mesothelioma cells breaking bad: loss of integrin α7 promotes cell motility and poor clinical outcomes in patients
- (2015) Dean J Burkin et al. JOURNAL OF PATHOLOGY
- Clinical significance of the integrin α6β4 in human malignancies
- (2015) Rachel L Stewart et al. LABORATORY INVESTIGATION
- Src family kinases and their role in hematological malignancies
- (2015) Matthew Ku et al. LEUKEMIA & LYMPHOMA
- The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
- (2015) L. Christiansson et al. MOLECULAR CANCER THERAPEUTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
- (2015) Laetitia Seguin et al. TRENDS IN CELL BIOLOGY
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
- (2015) S N Payne et al. Oncogenesis
- SRC: A Century of Science Brought to the Clinic
- (2015) Alexey Aleshin et al. NEOPLASIA
- Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
- (2014) E. Élez et al. ANNALS OF ONCOLOGY
- Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer
- (2014) Mareile Joka et al. ANTI-CANCER DRUGS
- Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
- (2014) S J Isakoff et al. BRITISH JOURNAL OF CANCER
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells
- (2014) Jianliang Zhang et al. CELL CYCLE
- Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer
- (2014) L. Pusztai et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib
- (2014) Poe-Hirr Hsyu et al. Drug Metabolism and Pharmacokinetics
- Targeting mTOR dependency in pancreatic cancer
- (2014) Douglas C Morran et al. GUT
- Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer
- (2014) Nina R. Shah et al. GYNECOLOGIC ONCOLOGY
- Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
- (2014) Thomas Semrad et al. International Journal of Clinical Oncology
- Therapeutic Targeting of Integrin αvβ6 in Breast Cancer
- (2014) Kate M. Moore et al. JNCI-Journal of the National Cancer Institute
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer
- (2014) Y. Pan et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
- (2014) E. Rozengurt et al. MOLECULAR CANCER THERAPEUTICS
- Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
- (2014) Bernardo Tavora et al. NATURE
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Src Inhibition Is Still a Relevant Target in Pancreatic Cancer
- (2014) T. J. George et al. ONCOLOGIST
- The Inhibition of Src Family Kinase Suppresses Pancreatic Cancer Cell Proliferation, Migration, and Invasion
- (2014) Dong Wook Je et al. PANCREAS
- Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
- (2014) I. M. Shapiro et al. Science Translational Medicine
- Identification and Validation of Src and Phospho-Src Family Proteins in Circulating Mononuclear Cells as Novel Biomarkers for Pancreatic Cancer
- (2014) Kenji Yokoi et al. Translational Oncology
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
- (2014) Anna Kreutzman et al. OncoImmunology
- Mechanotransduction Pathways Promoting Tumor Progression Are Activated in Invasive Human Squamous Cell Carcinoma
- (2013) S. Jan Ibbetson et al. AMERICAN JOURNAL OF PATHOLOGY
- Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
- (2013) S Boeck et al. BRITISH JOURNAL OF CANCER
- Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer
- (2013) M. Nobis et al. CANCER RESEARCH
- Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
- (2013) Michele Reni et al. EUROPEAN JOURNAL OF CANCER
- A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
- (2013) Minoti V. Apte et al. GASTROENTEROLOGY
- Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells
- (2013) Lara H. El Touny et al. JOURNAL OF CLINICAL INVESTIGATION
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
- (2013) C. E. Chee et al. ONCOLOGIST
- Cell Cycle-Dependent Rho GTPase Activity Dynamically Regulates Cancer Cell Motility and Invasion In Vivo
- (2013) Yoshinori Kagawa et al. PLoS One
- PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis
- (2013) G. R. Bean et al. Science Signaling
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
- (2012) S Boeck et al. BRITISH JOURNAL OF CANCER
- A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)
- (2012) L. Burt Nabors et al. CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- KRas Induces a Src/PEAK1/ErbB2 Kinase Amplification Loop That Drives Metastatic Growth and Therapy Resistance in Pancreatic Cancer
- (2012) J. A. Kelber et al. CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
- (2012) Timothy R. Donahue et al. CLINICAL CANCER RESEARCH
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
- (2012) Volker Heinemann et al. GUT
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
- (2012) Michael A Jacobetz et al. GUT
- A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
- (2012) David S. Hong et al. INVESTIGATIONAL NEW DRUGS
- A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
- (2012) Sil Kordes et al. INVESTIGATIONAL NEW DRUGS
- Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
- (2012) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the Yin and the Yang
- (2012) Evan G. Gomes et al. PANCREAS
- Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
- (2012) Sarat Chandarlapaty Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Central role of paxillin phosphorylation in regulation of LFA-1 integrins activity and lymphocyte migration
- (2012) Larisa Y. Romanova et al. Cell Adhesion & Migration
- A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
- (2011) M. N. Fornier et al. ANNALS OF ONCOLOGY
- Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
- (2011) M. Campone et al. ANNALS OF ONCOLOGY
- Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth
- (2011) Michael S. Samuel et al. CANCER CELL
- A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
- (2011) Richat Abbas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53
- (2011) P. Timpson et al. CANCER RESEARCH
- A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer
- (2011) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
- (2011) J. C. Montero et al. CLINICAL CANCER RESEARCH
- Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
- (2011) N. S. Nagaraj et al. CLINICAL CANCER RESEARCH
- Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
- (2011) Tanja Trarbach et al. INVESTIGATIONAL NEW DRUGS
- Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
- (2011) Mark R. Gilbert et al. JOURNAL OF NEURO-ONCOLOGY
- Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
- (2011) J. B. Stokes et al. MOLECULAR CANCER THERAPEUTICS
- Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis
- (2011) Alyssa L. Kennedy et al. MOLECULAR CELL
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- (2011) Peter Carmeliet et al. NATURE REVIEWS DRUG DISCOVERY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network
- (2011) Haoqiang Ying et al. Cancer Discovery
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
- (2010) I Garrido-Laguna et al. BRITISH JOURNAL OF CANCER
- Quantitative In vivo Imaging of the Effects of Inhibiting Integrin Signaling via Src and FAK on Cancer Cell Movement: Effects on E-cadherin Dynamics
- (2010) M. Canel et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma
- (2010) Guang-Hui Zhu et al. DIGESTIVE DISEASES AND SCIENCES
- Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- (2010) Jennifer P. Morton et al. GASTROENTEROLOGY
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer
- (2010) Daniel J. Renouf et al. INVESTIGATIONAL NEW DRUGS
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrins as Target: First Phase III Trial Launches, but Questions Remain
- (2010) Andrea Carter JNCI-Journal of the National Cancer Institute
- Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
- (2010) Nagathihalli S. Nagaraj et al. MOLECULAR CANCER THERAPEUTICS
- International network of cancer genome projects
- (2010) Thomas J. Hudson (Chairperson) et al. NATURE
- mTOR signaling and drug development in cancer
- (2010) Janet Dancey Nature Reviews Clinical Oncology
- Dasatinib treatment for Philadelphia chromosome-positive leukemias
- (2009) Hanna Jean Khoury et al. CANCER
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Mutant p53 Drives Invasion by Promoting Integrin Recycling
- (2009) Patricia A.J. Muller et al. CELL
- Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
- (2009) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
- (2009) N.V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells
- (2009) Jeanett Fischgräbe et al. INTERNATIONAL JOURNAL OF CANCER
- Adhesion signaling - crosstalk between integrins, Src and Rho
- (2009) S. Huveneers et al. JOURNAL OF CELL SCIENCE
- Involvement of Src Family Kinases in Substance P-Induced Chemokine Production in Mouse Pancreatic Acinar Cells and Its Significance in Acute Pancreatitis
- (2009) R. D. Ramnath et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
- (2009) W. A. Messersmith et al. MOLECULAR CANCER THERAPEUTICS
- Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
- (2009) Andrew R Reynolds et al. NATURE MEDICINE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Phosphorylated Caveolin-1 Regulates Rho/ROCK-Dependent Focal Adhesion Dynamics and Tumor Cell Migration and Invasion
- (2008) B. Joshi et al. CANCER RESEARCH
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds 5 1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
- (2008) A. D. Ricart et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
- (2008) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation